Maxigen Biotech Inc. Announces Bioport and Bioport Mini Intra-Articular Injection Prosthesis Obtains Ministry of Health of Russia Approval for Marketing
January 24, 2019 at 09:38 am
Maxigen Biotech Inc. announced that Bioport and Bioport Mini intra-articular injection prosthesis are comprised of highly purified sodium hyaluronate and manufactured by using aseptic filling technology. They are intended for management of osteoarthritic knee pain in patients with 3 and 5 injections per treatment to enhances synovial fluid viscoelasticity, reduces inflammatory response, protects articular tissues and eases osteoarthritic pain. Maxigen Biotech Inc. has complete set of intra-articular injection products in worldwide market including Taiwan, Eurpoe, Singapore, Indonesia and Russia. In the future, intra-articular
injection products can increase the global market and will have significant benefits for future revenue.